KARPAS 707H Human myeloma cell line suitable for the generation of stable human hybridomas for the creation of fully human monoclonal antibodies.
Publications:
Karpas et al. (2001) Proc. Natl. Acad. Sci. 98, 1799–1804
Vaisbourd et al. (2001) Hybridoma & Hybridomics, 20, 287–292
Cambridge Enterprise Limited is the exclusive licensor for the Karpas cell line portfolio.
